18:13 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
18:38 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute lymphoblastic leukemia (ALL) Mouse studies suggest hematopoietic stem cells (HSCs) expressing IFNα could help treat B cell ALL (B-ALL). In a mouse model of B-ALL, HSCs modified to express IFNα decreased leukemic cell growth...
18:00 , Oct 18, 2018 |  BC Extra  |  Clinical News

Keytruda, Inlyta combo headed for first-line RCC submissions

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab in combination with Inlyta axitinib met the primary endpoints vs. Sutent sunitinib in the Phase III KEYNOTE-426 trial as first-line treatment of renal cell carcinoma. Merck plans...
22:57 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Brain cancer; colorectal cancer; viral infection Mouse studies suggest inhibiting HPK1 kinase activity alone or in combination with PD-L1 inhibitors could help treat brain cancer, colorectal cancer and lymphocytic choriomeningitis virus (LCMV) infection. In mouse...
20:47 , Oct 5, 2018 |  BC Week In Review  |  Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

BioSense Global LLC (East Rutherford, N.J.) exercised its option under a 2017 deal to acquire exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs will receive an...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival (PFS) vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat...
22:08 , Sep 11, 2018 |  BC Extra  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat previously...
16:41 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...
18:15 , Aug 31, 2018 |  BC Extra  |  Clinical News

AZ's anifrolumab misses in Phase III for lupus

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed...